Search

Your search keyword '"Rodeghiero, F"' showing total 1,233 results
Start Over Author "Rodeghiero, F"
1,233 results on '"Rodeghiero, F"'

6. Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia

Author

Tosetto, A., Rocca, Bianca, Petrucci, Giovanna, Betti, S., Soldati, D., Rossi, Elena, Timillero, A., Cavalca, V., Porro, B., Iurlo, A., Cattaneo, D., Bucelli, C., Dragani, A., Di Ianni, M., Ranalli, P., Palandri, F., Vianelli, N., Beggiato, E., Lanzarone, G., Ruggeri, M., Carli, G., Elli, E. M., Priolo, S., Randi, M. L., Bertozzi, I., Loscocco, G. G., Ricco, A., Specchia, G., Vannucchi, A. M., Rodeghiero, F., De Stefano, Valerio, Patrono, Carlo, Rocca B. (ORCID:0000-0001-8304-6423), Petrucci G. (ORCID:0000-0002-9280-3673), Rossi E. (ORCID:0000-0002-7572-9379), De Stefano V. (ORCID:0000-0002-5178-5827), Patrono C., Tosetto, A., Rocca, Bianca, Petrucci, Giovanna, Betti, S., Soldati, D., Rossi, Elena, Timillero, A., Cavalca, V., Porro, B., Iurlo, A., Cattaneo, D., Bucelli, C., Dragani, A., Di Ianni, M., Ranalli, P., Palandri, F., Vianelli, N., Beggiato, E., Lanzarone, G., Ruggeri, M., Carli, G., Elli, E. M., Priolo, S., Randi, M. L., Bertozzi, I., Loscocco, G. G., Ricco, A., Specchia, G., Vannucchi, A. M., Rodeghiero, F., De Stefano, Valerio, Patrono, Carlo, Rocca B. (ORCID:0000-0001-8304-6423), Petrucci G. (ORCID:0000-0002-9280-3673), Rossi E. (ORCID:0000-0002-7572-9379), De Stefano V. (ORCID:0000-0002-5178-5827), and Patrono C.

Published
2022

16. Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study

Author

EIKENBOOM, J., HILBERT, L, RIBBA, A.S., HOMMAIS, A., HABART, D., MESSENGER, S., AL-BUHAIRAN, A., GUILLIATT, A., LESTER, W., MAZURIER, C., MEYER, D., FRESSINAUD, E., BUDDE, U., WILL, K., SCHNEPPENHEIM, R., OBSER, T., MARGGRAF, O., ECKERT, E., CASTAMAN, G., RODEGHIERO, F., FEDERICI, A.B., BATLLE, J., GOUDEMAND, J., INGERSLEV, J., LETHAGEN, S., HILL, F., PEAKE, I., and GOODEVE, A.

Published
2009
Full Text
View/download PDF

19. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD)

Author

BUDDE, U., SCHNEPPENHEIM, R., EIKENBOOM, J., GOODEVE, A., WILL, K., DREWKE, E., CASTAMAN, G., RODEGHIERO, F., FEDERICI, A.B., BATLLE, J., PÉREZ, A., MEYER, D., MAZURIER, C., GOUDEMAND, J., INGERSLEV, J., HABART, D., VORLOVA, Z., HOLMBERG, L., LETHAGEN, S., PASI, J., HILL, F., and PEAKE, I.

Published
2008
Full Text
View/download PDF

21. Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper

Author

Barbui, T, De Stefano, V, Falanga, A, Finazzi, G, Martinelli, I, Rodeghiero, F, Vannucchi, A, Barosi, G, Barbui T, De Stefano V, Falanga A, Finazzi G, Martinelli I, Rodeghiero F, Vannucchi AM, Barosi G, Barbui, T, De Stefano, V, Falanga, A, Finazzi, G, Martinelli, I, Rodeghiero, F, Vannucchi, A, Barosi, G, Barbui T, De Stefano V, Falanga A, Finazzi G, Martinelli I, Rodeghiero F, Vannucchi AM, and Barosi G

Abstract

This article presents the results of a group discussion among an ad hoc constituted Panel of experts aimed at highlighting unmet clinical needs (UCNs) in the management of thrombotic risk and thrombotic events associated with Philadelphia-negative myeloproliferative neoplasms (Ph-neg MPNs). With the Delphi technique, the challenges in Ph-neg MPN-associated thrombosis were selected. The most clinically relevant UCNs resulted in: (1) providing evidence of the benefits and risks of direct oral anticoagulants, (2) providing evidence of the benefits and risks of cytoreduction in patients with splanchnic vein thrombosis without hypercythemia, (3) improving knowledge of the role of the mutated endothelium in the pathogenesis of thrombosis, (4) improving aspirin dosing regimens in essential thrombocythemia, (5) improving antithrombotic management of Ph-neg MPN-associated pregnancy, (6) providing evidence for the optimal duration of anticoagulation for prophylaxis of recurrent VTE, (7) improving knowledge of the association between somatic gene mutations and risk factors for thrombosis, and (8) improving the grading system of thrombosis risk in polycythemia vera. For each of these issues, proposals for advancement in research and clinical practice were addressed. Hopefully, this comprehensive overview will serve to inform the design and implementation of new studies in the field.

Published
2019

25. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1VWD)

Author

TOSETTO, A., RODEGHIERO, F., CASTAMAN, G., BERNARDI, M., BERTONCELLO, K., GOODEVE, A., FEDERICI, A.B., BATLLE, J., MEYER, D., MAZURIER, C., GOUDEMAND, J., EIKENBOOM, J., SCHNEPPENHEIM, R., BUDDE, U., INGERSLEV, J., VORLOVA, Z., HABART, D., HOLMBERG, L., LETHAGEN, S., PASI, J., HILL, F., and PEAKE, I.

Published
2007
Full Text
View/download PDF

38. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD

Author

EIKENBOOM, J., VAN MARION, V., PUTTER, H., GOODEVE, A., RODEGHIERO, F., CASTAMAN, G., FEDERICI, A.B., BATLLE, J., MEYER, D., MAZURIER, C., GOUDEMAND, J., SCHNEPPENHEIM, R., BUDDE, U., INGERSLEV, J., VORLOVA, Z., HABART, D., HOLMBERG, L., LETHAGEN, S., PASI, J., HILL, F., and PEAKE, I.

Published
2006
Full Text
View/download PDF

46. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers

Author

Cantoni, S, Carpenedo, M, Mazzucconi, M, De Stefano, V, Carrai, V, Ruggeri, M, Specchia, G, Vianelli, N, Pane, F, Consoli, U, Artoni, A, Zaja, F, D'Adda, M, Visentin, A, Ferrara, F, Barcellini, W, Caramazza, D, Baldacci, E, Rossi, E, Ricco, A, Ciminello, A, Rodeghiero, F, Nichelatti, M, Cairoli, R, Cantoni S, Carpenedo M, Mazzucconi MG, De Stefano V, Carrai V, Ruggeri M, Specchia G, Vianelli N, Pane F, Consoli U, Artoni A, Zaja F, D'adda M, Visentin A, Ferrara F, Barcellini W, Caramazza D, Baldacci E, Rossi E, Ricco A, Ciminello A, Rodeghiero F, Nichelatti M, Cairoli R, Cantoni, S, Carpenedo, M, Mazzucconi, M, De Stefano, V, Carrai, V, Ruggeri, M, Specchia, G, Vianelli, N, Pane, F, Consoli, U, Artoni, A, Zaja, F, D'Adda, M, Visentin, A, Ferrara, F, Barcellini, W, Caramazza, D, Baldacci, E, Rossi, E, Ricco, A, Ciminello, A, Rodeghiero, F, Nichelatti, M, Cairoli, R, Cantoni S, Carpenedo M, Mazzucconi MG, De Stefano V, Carrai V, Ruggeri M, Specchia G, Vianelli N, Pane F, Consoli U, Artoni A, Zaja F, D'adda M, Visentin A, Ferrara F, Barcellini W, Caramazza D, Baldacci E, Rossi E, Ricco A, Ciminello A, Rodeghiero F, Nichelatti M, and Cairoli R

Abstract

Sequential use of the TPO-RAs romiplostim and eltrombopag in ITP patients failing either agent was retrospectively evaluated to assess efficacy and impact of clinical characteristics on outcome. Patients were grouped into 5 categories: efficacy issues: 1st TPO-RA failure; loss of response; non-efficacy issues: platelet fluctuations; patient's preference; adverse event development. Either one TPO-RA sequence was analyzed at 3 month and at last follow-up. 106/546 patients on TPO-RA underwent switch and 65% achieved, regained or maintained a short- term response independent of switch sequence, gender or age; lower response rates were associated with lines of previous therapy; disease duration lowers probability to respond. Clinically, patients switched for efficacy issue did not differ from those switched for non-efficacy issues. Response was achieved/regained in 57.8% of patients switched for efficacy issues, the lowest response rates were observed in non-responders to 1st TPO-RA; 80% of patients switched for non-efficacy issues maintained a response. Platelet fluctuation resolved in 44.4%. Of the 49 patients evaluable for long-term outcome, 27 were in response on therapy; 16 discontinued the TPO-RA for reasons other than efficacy, while only 6 were non responders. We confirm the efficacy of TPO-RA switch; once achieved, response to the 2nd TPO-RA seems durable.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results